Open an account

Kiniksa Pharmaceuticals International

KNSA · NASDAQ

$83.17+$3.69 (+4.64%)TodayMarket closed ·
Prev close $79.48

About KNSA

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Employees
366
Headquarters
London
Listed
May 24, 2018
Sector
Health Care
Industry
Biotechnology
Website
kiniksa.com

KNSA key statistics

Market cap
6.49B
Price-earnings ratio
81.10
Dividend yield
—
Average volume
541.62K
Volume
1.24M
Open price
$80.25
High today
$83.78
Low today
$79.88
52 Week high
$82.98
52 Week low
$35.20

Kiniksa Pharmaceuticals International (KNSA) at a glance

Kiniksa Pharmaceuticals International (KNSA) last traded at $83.17, with a market cap of 6.49B and a price-to-earnings ratio of 81.10.

Today the stock has traded between $79.88 and $83.78. The current price is 4.1% above the day's low and 0.7% below its high.

Volume so far is 1.24M shares, above the average of 541.62K shares a day.

Over the past year Kiniksa Pharmaceuticals International has ranged from $35.20 to $82.98, and now sits 100% of the way up that range.

Kiniksa Pharmaceuticals International met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.30 per share against an estimate of $0.3047.

The average analyst price target is $98.65, 18.6% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $98.65
Low
$87.87
Now
$83.17
High
$113.40

KNSA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 70.8% on average.

  1. Q3 FY24: reported -$0.18 per share against an estimate of $0.0326
  2. Q4 FY24: reported -$0.12 per share against an estimate of -$0.002
  3. Q1 FY25: reported $0.11 per share against an estimate of $0.0428
  4. Q2 FY25: reported $0.23 per share against an estimate of $0.1858
  5. Q3 FY25: reported $0.23 per share against an estimate of $0.3298
  6. Q4 FY25: reported $0.17 per share against an estimate of $0.3819
  7. Q1 FY26: reported $0.27 per share against an estimate of $0.2053
  8. Q2 FY26: reported $0.30 per share against an estimate of $0.3047

KNSA news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Insights Ahead: Kiniksa Pharmaceuticals's Quarterly Earnings

  • Avi Kapoor

    Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

  • Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook

  • Avi Kapoor

    Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

  • Avi Kapoor

    Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.